Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works

Mechanisms of hepatic stellate cell activation

Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · see citing works

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · see citing works

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · see citing works

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 739 · see citing works

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · see citing works

Pharmacological Inhibition of the Chemokine CCL2 (MCP-1) Diminishes Liver Macrophage Infiltration and Steatohepatitis in Chronic Hepatic Injury

Baeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609 · see citing works

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557 · see citing works

CCR1 and CCR5 promote hepatic fibrosis in mice

Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431 · see citing works

Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis

Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323 · see citing works

Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism

Lefere, S., & Tacke, F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.004 · Cited by 278 · see citing works

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice

Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., Hittatiya, K., Eulberg, D., Luedde, T., Trautwein, C., et al. (2014) · Hepatology · doi:10.1002/hep.26783 · Cited by 270 · see citing works

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

Berres, M., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K. L., Berg, T., Gaßler, N., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41732 · Cited by 264 · see citing works

Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol‐Induced Liver Damage, Steatosis, and Inflammation in Mice

Ambade, A., Lowe, P., Kodys, K., Catalano, D. E., Gyöngyösi, B., Cho, Y., Iracheta‐Vellve, A., Adejumo, A., Saha, B., Calenda, C. D., et al. (2018) · Hepatology · doi:10.1002/hep.30249 · Cited by 213 · see citing works

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209 · see citing works

Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model

Teng, K., Han, J., Zhang, X., Hsu, S., He, S., Wani, N. A., Barajas, J. M., Snyder, L. A., Frankel, W. L., Caligiuri, M. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0124 · Cited by 134 · see citing works

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

Tacke, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442436 · Cited by 122 · see citing works

Functional role of CCL5/RANTES for HCC progression during chronic liver disease

Mohs, A., Kuttkat, N., Reißing, J., Zimmermann, H. W., Sonntag, R., Proudfoot, A. E. J., Youssef, S. A., de Bruin, A., Cubero, F. J., & Trautwein, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.011 · Cited by 92 · see citing works

Inflammation-Induced Hepatocellular Carcinoma Is Dependent on Ccr5 in Mice

Barashi, N., Weiss, I. D., Wald, O., Wald, H., Beider, K., Abraham, M., Klein, S., Goldenberg, D., Axelrod, J. H., Pikarsky, E., et al. (2013) · Hepatology · doi:10.1002/hep.26403 · Cited by 77 · see citing works

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

Lefebvre, E. A., Gottwald, M. D., Lasseter, K. C., Chang, W., Willett, M. S., Smith, P. F., Somasunderam, A., & Utay, N. S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12397 · Cited by 57 · see citing works

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy

Gale, J. D., Gilbert, S. A., Blumenthal, S. S., Elliott, T., Pérgola, P. E., Goteti, K., Scheele, W. H., & Huguet, C. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.07.010 · Cited by 50 · see citing works

The role of macrophages in obesity-driven chronic liver disease

Devisscher, L., Verhelst, X., Colle, I. O., Vlierberghe, H. V., & Geerts, A. M. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ru0116-016r · Cited by 44 · see citing works

Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line

Coppola, N., Perna, A., Lucariello, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26485 · Cited by 36 · see citing works

CCL5 secreted from bone marrow stromal cells stimulates the migration and invasion of Huh7 hepatocellular carcinoma cells via the PI3K-Akt pathway

Bai, H., Weng, Y., Bai, S., Jiang, Y., LI, B., He, F., Zhang, R., Yan, S., Deng, F., Wang, J., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2421 · Cited by 25 · see citing works

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Gale, J. D., Berger, B. B., Gilbert, S. A., Popa, S., Sultan, M. B., Schachar, R. A., Girgenti, D., & Huguet, C. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22731 · Cited by 21 · see citing works

Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH

Daemen, S., Gainullina, A., Kalugotla, G., He, L., Chan, M. M., Beals, J. W., Liss, K. H., Klein, S., Feldstein, A. E., Finck, B. N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108626 · Cited by 378 · see citing works

Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH

Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.004 · Cited by 220 · see citing works

Novel therapeutic targets for cholestatic and fatty liver disease

Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works

Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126696 · Cited by 59 · see citing works

Liver macrophages revisited: The expanding universe of versatile responses in a spatiotemporal context

Guillot, A., & Tacke, F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000491 · Cited by 45 · see citing works

Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis

Lan, T., Ruiz, L., Liu, W., et al. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01222-3

Correction of endotoxemia in patients with nonalcoholic steatohepatitis

Собирова, Г. Н., Каримов, М. М., & Alavi, A. (2011) · Medical and Health Science Journal · doi:10.15208/mhsj.2011.180 · Cited by 2 · see citing works

Mixed steatohepatitis: more questions than answers (Part 1)

Raikhelson, K. L., Александровна, К. Э., & Владимировна, П. Е. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.12.200470 · Cited by 20 · see citing works

[Clinical and biochemical characteristics in patients with histology compatible with steatothepatitis in National Hospital Arzobispo Loayza, Lima, Peru, from 2010 to 2012].

Matos, A., Cabello, K. S. T., Miranda, A. L., et al. (2017) · PubMed

The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics

Gruszewska, E., Gudowska-Sawczuk, M., Wójtowicz, E., et al. (2015) · Clinical Laboratory · doi:10.7754/clin.lab.2015.150434 · Cited by 2 · see citing works